June 17th 2021
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
November 18th 2014
June 13th 2013
June 12th 2013
Disinfecting all ICU patients significantly reduces MRSA
May 30th 2013Decolonization of all intensive care unit (ICU) patients with antimicrobial soap and ointment significantly reduces all bloodstream infections, including methicillin-resistant Staphylococcus aureus (MRSA), according to a study published in the New England Journal of Medicine.
Managed care approach to substance abuse treatment
May 20th 2013An examination of people’s behaviors as they relate to drug use in the 20th century has shown that people will expend a large amount of energy to acquire any agent that has the ability to alter their minds, bodies, or behaviors in order to achieve a euphoric effect.
Guideline recommendations issued for molecular testing, targeted therapies in lung cancer
April 8th 2013The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) recently issued evidence-based guidelines on molecular testing in lung cancer, and support the recommendation that physicians conduct testing in advanced non-small cell lung cancer patients at the time of diagnosis or at the time of recurrence or progression.
FDA Actions in Brief February 2013
February 28th 2013Recent FDA Approvals (through February 2013) related to (Ado-trastuzumab, Kadcyla, Genentech, Everolimus, Zortress, Novartis, Adapalene, benzoyl peroxide, Epiquo, Galderma, pomalidomide, Pomalyst, Celgene, alogliptin, Nesina, Takeda Pharmaceuticals, Kazano, Oseni, imatinib, Gleevec, mesalamine, Delzicol, Warner Chilcott, mipomersen sodium, Kynamro, Genzyme, Isis Pharmaceuticals, Merck, Oxutrol for Women, glycerol phenylbutyrate, Ravicti, Hyperion Therapeutics, pneumococcal 13-valent Conjugate Vaccine, Prevnar 13, Pfizer
An update in attention deficit/hyperactivity disorder
February 28th 2013Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder in children. New formulations of stimulants and nonstimulants allow for individualization of therapy for patients to receive the maximum benefit while minimizing side effects.
Community-based intervention can help reduce mortality from opioid overdose
February 28th 2013In the study of communities in Massachusetts with high numbers of opioid overdose deaths, implementation of overdose education and naloxone distribution (OEND) were associated with a significant reduction in opioid overdose death rates.
Extended dabigatran use reduces risk of recurrent VTE, study finds
February 27th 2013Dabigatran used beyond the initial 3 months of treatment at a dose of 150 mg twice daily reduced the risk of recurrent venous thromboembolism (VTE), according to a study published February 21 in the New England Journal of Medicine.